QRG Capital Management Inc. Invests $489,000 in BioNTech SE Sponsored ADR $BNTX

QRG Capital Management Inc. bought a new stake in BioNTech SE Sponsored ADR (NASDAQ:BNTX) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 4,963 shares of the company’s stock, valued at approximately $489,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Royal Bank of Canada lifted its position in BioNTech by 95.9% in the first quarter. Royal Bank of Canada now owns 7,177 shares of the company’s stock valued at $653,000 after purchasing an additional 3,514 shares during the last quarter. NewEdge Advisors LLC purchased a new position in shares of BioNTech in the first quarter worth $167,000. Generali Investments CEE investicni spolecnost a.s. raised its holdings in BioNTech by 166.7% during the 2nd quarter. Generali Investments CEE investicni spolecnost a.s. now owns 3,200 shares of the company’s stock valued at $341,000 after buying an additional 2,000 shares during the last quarter. Platinum Investment Management Ltd. purchased a new stake in BioNTech during the 2nd quarter valued at $1,582,000. Finally, Mirae Asset Global Investments Co. Ltd. boosted its position in BioNTech by 14.9% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,109 shares of the company’s stock valued at $437,000 after buying an additional 533 shares during the period. 15.52% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

BNTX has been the topic of a number of analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of BioNTech in a research report on Friday, January 9th. JPMorgan Chase & Co. reduced their price target on BioNTech from $121.00 to $120.00 and set a “neutral” rating on the stock in a report on Thursday, October 23rd. Jefferies Financial Group reiterated a “buy” rating and issued a $151.00 price objective on shares of BioNTech in a report on Wednesday, December 3rd. UBS Group raised BioNTech to a “hold” rating in a research note on Thursday, December 4th. Finally, Morgan Stanley restated an “overweight” rating and set a $134.00 target price on shares of BioNTech in a report on Monday, November 3rd. Eleven investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, BioNTech presently has an average rating of “Moderate Buy” and a consensus price target of $140.03.

BioNTech Trading Up 0.4%

NASDAQ BNTX opened at $118.47 on Friday. The firm has a market capitalization of $26.68 billion, a PE ratio of -45.05 and a beta of 1.40. The stock’s 50 day moving average is $99.14 and its 200 day moving average is $103.69. BioNTech SE Sponsored ADR has a twelve month low of $81.20 and a twelve month high of $126.77. The company has a quick ratio of 7.02, a current ratio of 7.12 and a debt-to-equity ratio of 0.01.

BioNTech (NASDAQ:BNTX) last posted its quarterly earnings data on Monday, November 3rd. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.75 by ($0.89). BioNTech had a negative return on equity of 3.03% and a negative net margin of 17.91%.The firm had revenue of $1.78 billion during the quarter, compared to the consensus estimate of $1.21 billion. During the same quarter last year, the company posted $0.81 EPS. BioNTech’s revenue for the quarter was up 22.0% compared to the same quarter last year. Research analysts forecast that BioNTech SE Sponsored ADR will post -3.88 earnings per share for the current fiscal year.

About BioNTech

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.